Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) announced it is evaluating three potential locations in the United States for its planned integrated iodine and barium contrast drug manufacturing facility, marking a step toward establishing a fully domestic supply chain for critical medical imaging agents. The company is completing a comprehensive technical, regulatory, economic, and logistical analysis of candidate sites in Oklahoma and Texas, with a strong emphasis on proximity to iodine brine sources, infrastructure, and government incentive packages.
According to the company, the final site selection will be based on the most attractive overall combination of factors, including the strength of incentive and support packages offered by state and local authorities. Key evaluation criteria include proximity to iodine brine sources—expected to support an estimated +70% of future revenue—logistics, infrastructure, access to skilled labor, and the availability of government incentives. Voyageur is actively engaging with economic development authorities across multiple U.S. jurisdictions to optimize project economics and accelerate development timelines.
Strategic advantages of the shortlisted jurisdictions in Oklahoma and Texas include proximity to Voyageur’s iodine extraction initiatives in Oklahoma’s Anadarko Basin, robust transportation infrastructure for efficient North American and global distribution, access to skilled labor and abundant municipal water supply, reliable infrastructure, a competitive business climate with low taxes, and strong local, state, and federal incentives supporting advanced manufacturing, pharmaceutical and API production, critical minerals processing, and strategic supply chain onshoring.
The pharmaceutical manufacturing facility will receive concentrated iodine liquor produced through Voyageur’s proprietary closed-loop Streamlined Iodine Process directly from its Oklahoma brine operations, together with high-purity barite from the Frances Creek project. Unlike conventional contrast media manufacturers that depend on imported iodine flakes or intermediates and energy-intensive synthetic precipitated barium sulfate, this integrated GMP campus will combine on-site iodine-to-API synthesis with barite upgrading into USP-grade material and sterile injectable manufacturing. Management believes this will deliver the first fully domestic, vertically integrated supply chain for both iodinated and barium contrast agents at materially lower cost, with superior sustainability and supply security for U.S. hospitals, government customers, and international distribution.
Key anticipated project highlights include cost leadership through vertical integration, significant opportunities for U.S. federal and state funding and incentives, the creation of 150–250 direct high-skilled jobs in manufacturing, engineering, quality assurance, laboratory, and operations, plus substantial indirect employment through construction and suppliers. Once at full scale, the facility is expected to generate significant annual economic activity, major local tax revenue, and support for regional supply chains. Planned collaboration with post-secondary institutions aims to establish pharmaceutical training programs, co-op placements, and talent pipelines in chemical engineering and pharmaceutical sciences. Centrally located to serve the North American contrast media market, the facility is expected to enable efficient management of iodine and barium contrast production while supporting iodine supply for the company’s collaboration with Bayer on the Oklahoma iodine prill project.
Brent Willis, CEO of Voyageur Pharmaceuticals, stated: “This location decision optimizes logistics between our Oklahoma iodine sources and Canadian barite resources while providing the infrastructure required for GMP-compliant manufacturing. We are evaluating multiple strong jurisdictions and will select the site that delivers the most compelling overall package, including the strongest incentive support. The jurisdiction that provides Voyageur with the most significant incentive package will secure this transformative project and its substantial long-term economic benefits.”
Site preparation and detailed engineering are targeted to commence in late 2026, with first production expected in Q4 2028–2029, subject to financing, regulatory approvals, and other customary conditions. This announcement builds on Voyageur’s ongoing collaboration with Bayer and recent advancements in its barium contrast portfolio, including Health Canada-approved products already in commercial use. Management believes the project aligns with U.S. priorities for domestic critical and strategic minerals, pharmaceutical onshoring of strategic drugs, and rural economic development.
Voyageur Pharmaceuticals is a Canadian company focused on becoming a low-cost, vertically integrated producer of barium and iodine Active Pharmaceutical Ingredients (APIs) and finished imaging contrast agents. The company has already developed five barium contrast products that hold Health Canada licenses and are currently generating revenue in Canada. By owning 100% of the high-grade, metal-free Frances Creek barite project, Voyageur controls its own secure, domestic source of pharmaceutical-grade barium sulfate. In parallel, its patent-pending Mueller process enables low-cost extraction of iodine from mineral brine water, and its proprietary Streamline manufacturing technology processes that iodine directly into finished iodine contrast drugs within a single, integrated production chain.
For further information, visit https://voyageurpharmaceuticals.ca.
